Literature DB >> 11752098

Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.

Lars Eckardt1, Günter Breithardt, Wilhelm Haverkamp.   

Abstract

There is growing concern that antipsychotic drugs that prolong the QT interval almost always increase the risk for patients to develop life-threatening ventricular tachyarrhythmias (VTs) of the torsade de pointes type. We therefore sought to compare the electrophysiologic effects of the psychotropic agent sertindole, which prolongs cardiac repolarization by inhibiting the rapid component of the delayed rectifier potassium current (I(Kr)) but has a low torsadogenic potential to the antiarrhythmic agent dl-sotalol. In 18 Langendorff-perfused rabbit hearts, sotalol (10 microM, n = 8) and sertindole (0.5, 1.0, and 1.5 microM; n = 10) led to significant and comparable QT prolongation. In the presence of sotalol, torsade de pointes reproducibly occurred in atrioventricular node-blocked hearts after lowering the potassium concentration to 1.5 mM. High doses of sertindole (1.5 microM) only caused monomorphic VT (n = 4) and nonsustained polymorphic VT (n = 2) in the presence of QRS prolongation. Multiple simultaneous epi- and endocardial monophasic action potentials and a volume-conducted ECG demonstrated widening of the T/U wave, early afterdepolarizations, and increased dispersion of repolarization in the presence of dl-sotalol. In contrast to sotalol, QT and monophasic action potential prolongation were cycle length-independent in the presence of sertindole. Sertindole had no significant effect on transmural or interventricular dispersion of repolarization. Early afterdepolarizations did not occur. Despite comparable QT prolongation, sertindole did not display the proarrhythmic profile typical of other blockers of I(Kr) such as dl-sotalol. It is likely that a different mode of interaction between sertindole and the channel and/or additional pharmacological effects of sertindole, e.g., its ability to inhibit I(Na) and/or its ability to block alpha(1)-receptors, play a role.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752098     DOI: 10.1124/jpet.300.1.64

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

Review 1.  Introduction to sertindole in clinical practice.

Authors:  Joseph Peuskens
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  Case histories illustrating the utility of sertindole in clinical practice.

Authors:  Peter Schuck; Hans van den Ameele; Peeter Jaanson; Vincent Ryckmans; Chris Hawley
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 3.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Giant inverted T waves and substantial QT interval prolongation induced by azithromycin in an elderly woman with renal insufficiency.

Authors:  Tongtong Yu; Tiesheng Niu
Journal:  Can Fam Physician       Date:  2014-11       Impact factor: 3.275

Review 5.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

Review 6.  Emerging treatments in the management of schizophrenia - focus on sertindole.

Authors:  Maria Rosaria A Muscatello; Antonio Bruno; Gianluca Pandolfo; Umberto Micò; Salvatore Settineri; Rocco Zoccali
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

7.  Emerging role of sertindole in the management of schizophrenia.

Authors:  Stephanie L Cincotta; Joshua S Rodefer
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 8.  A review of the efficacy, tolerability and safety of sertindole in clinical trials.

Authors:  Lowijs Perquin; Tilman Steinert
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  The role of the Na+/Ca2+ exchanger, I(Na) and I(CaL) in the genesis of dofetilide-induced torsades de pointes in isolated, AV-blocked rabbit hearts.

Authors:  Attila S Farkas; Péter Makra; Norbert Csík; Szabolcs Orosz; Michael J Shattock; Ferenc Fülöp; Tamás Forster; Miklós Csanády; Julius Gy Papp; András Varró; András Farkas
Journal:  Br J Pharmacol       Date:  2009-02-16       Impact factor: 8.739

Review 10.  Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.